Senior Associate Scientist

New York City

Full-time

Permanent employee

Your mission

MeiraGTx is seeking an outstanding Senior Associate Scientist with extensive experience in in vivo animal studies to join our growing R&D team. The successful candidate will be primarily responsible for conducting and supporting animal experiments and will also contribute to a variety of laboratory-based research activities. The applicant will be required to present results and updates at project team meetings, maintain accurate and well-organized experiment records. The qualified candidate will work independently and as part of a team to closely collaborate with other team members in developing novel therapies.

Job Description

Major Responsibilities

Execute the animal study plan.
Animal drug administration via various administration routes.
Animal health monitoring and metabolic assessment.
Animal tissue and blood sample collection and processing.
Document the observations and assessments in an animal study.
Collaborate and interact with colleagues, complete assigned duties.
Comply with company training and policies.

Qualifications

BSc or MSc degree in Biology, Molecular and cellular biology, or related field.
5 to 8 years’ experience in laboratory animal care, handling, management, and in vivo animal studies.
Extensively experienced and highly proficient in various routes of administration, such as PO, IP, IV etc.
Highly experienced in tissue sample collection and processing.
Hands-on experience in mammalian cell culture, cell transfection, ELISA assays and molecular techniques.
Strong work ethic and professionalism, high level of responsibility, attention to detail, initiative, and a proactive attitude toward assigned tasks.
Self-motivated, energetic and able to work in a diverse team environment.

About us

MeiraGTx is a clinical-stage gene therapy company focused on developing potentially curative treatments for patients living with serious diseases. We currently have six programs in clinical development including three ocular indications, a salivary gland condition, and a Parkinson’s disease program. Our initial focus on diseases of the eye, salivary gland and central nervous system is based on the significant unmet medical need coupled with the high potential gene therapy has to provide meaningful clinical benefit in these areas. With headquarters in New York and London, our global footprint provides us the opportunity to partner with leading institutions around the world, allowing us to deepen our understanding of diseases and their progression.

Our team was built with deep expertise in gene therapy development, allowing us to efficiently advance our programs from preclinical to clinical development. Our core capabilities in viral vector design and optimization and gene therapy manufacturing give us a differentiated approach to developing gene therapies. Additionally, we are developing proprietary technology to potentially enable innovative gene therapy treatments whose expression can be turned on and off with an easily administered small molecule. We believe temporal control of gene therapy products has the potential to transform the gene therapy landscape.

Our state-of-the-art manufacturing facility, completed in early 2018, was designed to meet global regulatory requirements, including the current good manufacturing practices (cGMP) required by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK and the U.S. Food and Drug Administration (FDA). The 29,000-square foot facility has the flexibility and capacity to produce sufficient product for all our clinical trials and will scale to commercial capacity.